
    
      This is a Phase 1, fixed sequence, open-label study in healthy subjects, performed at a
      single study center. This study will consist of 3 treatment periods to assess the PK of
      midazolam when administered alone and in combination with multiple doses of AZD5718.

      The study will comprise:

        -  A screening period of maximum 28 days;

        -  Three treatment periods during which subjects will be resident from the day before first
           dosing (Day -1) until at least 24 hours after last dosing (Day 7); discharged on the
           morning of Day 8, and;

        -  A final Follow-up Visit within 5 to 7 days after the last administration of
           investigational medicinal product (IMP).
    
  